Literature DB >> 23648461

Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis.

Laszlo J Karai1, Marshall E Kadin, Eric D Hsi, Jason C Sluzevich, Rhett P Ketterling, Ryan A Knudson, Andrew L Feldman.   

Abstract

Lymphomatoid papulosis (LyP) is an indolent cutaneous lymphoproliferative disorder with clinical and pathologic features overlapping those of both reactive conditions and aggressive lymphomas. Recurrent genetic abnormalities in LyP have not been previously identified. Here, we describe the clinical, immunophenotypic, and genetic characteristics of cutaneous lymphoproliferative lesions showing distinctive and previously undescribed histologic features in 11 patients. All patients were older adults (67 to 88 y) with predominantly localized lesions and clinical presentations suggesting benign inflammatory dermatoses or low-grade epithelial tumors. Histologically, lesions showed a biphasic growth pattern, with small cerebriform lymphocytes in the epidermis and larger transformed lymphocytes in the dermis. All had a T-cell immunophenotype. The pathologic features raised the possibility of an aggressive T-cell lymphoma such as transformed mycosis fungoides. However, no patient developed disseminated skin disease or extracutaneous spread. Untreated lesions regressed spontaneously. All cases harbored chromosomal rearrangements of the DUSP22-IRF4 locus on 6p25.3. The overall findings suggest that these cases represent a newly recognized LyP subtype characterized by 6p25.3 rearrangements. The benign clinical course in all 11 patients despite pathologic features mimicking an aggressive lymphoma emphasizes the importance of clinicopathologic correlation, incorporating molecular genetic analysis when possible, during the evaluation of cutaneous lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648461     DOI: 10.1097/PAS.0b013e318282d01e

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  29 in total

1.  Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Authors:  Xiaoming Xing; Thomas J Flotte; Mark E Law; Anthony J Blahnik; Wee-Joo Chng; Gaofeng Huang; Ryan A Knudson; Rhett P Ketterling; Julie C Porcher; Stephen M Ansell; Jagmohan Sidhu; Ahmet Dogan; Andrew L Feldman
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

2.  Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

Authors:  Rebecca L King; Linda N Dao; Ellen D McPhail; Elaine S Jaffe; Jonathan Said; Steven H Swerdlow; Christopher A Sattler; Rhett P Ketterling; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; Sarah E Gibson; Sarah L Ondrejka; Alina Nicolae; William R Macon; Surendra Dasari; Edgardo Parrilla Castellar; Andrew L Feldman
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

3.  Secondary cutaneous involvement by systemic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma with 6p25.3 rearrangement.

Authors:  Andrew L Feldman; Karen L Grogg; Ryan A Knudson; David J Inwards
Journal:  Histopathology       Date:  2015-06-19       Impact factor: 5.087

Review 4.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

5.  DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers.

Authors:  Arantza Onaindia; Sonia González de Villambrosía; Lucía Prieto-Torres; Socorro M Rodríguez-Pinilla; Santiago Montes-Moreno; Carmen González-Vela; Miguel A Piris
Journal:  Haematologica       Date:  2018-10-25       Impact factor: 9.941

6.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

Review 7.  Cutaneous T-cell Lymphoma.

Authors:  Melissa Pulitzer
Journal:  Clin Lab Med       Date:  2017-09       Impact factor: 1.935

Review 8.  CD30+ Lymphoproliferative Disorders of the Skin.

Authors:  Maxwell B Sauder; John T O'Malley; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

Review 9.  [Cutaneous lymphomas: new entities and rare variants].

Authors:  W Kempf; C Mitteldorf
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 10.  Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.

Authors:  Meenal Kheterpal; Neha Mehta-Shah; Pooja Virmani; Patricia L Myskowski; Alison Moskowitz; Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.